”A biosensor that measures without meaning is not a medical device. It is an expensive anxiety machine.”
Data without a decision is just noise - A paid subscription to Noise, Anxiety or Cortisol
A biosensor that measures without meaning is not a medical device. It is an expensive anxiety machine.
Now take that problem and move it into something far more personal. A growing category called FemTech, short for female technology, has brought this same wearable logic into women’s hormonal health. Cycle tracking. Fertility monitoring. Perimenopause detection. Devices and apps designed specifically to measure and interpret the female body.
The intention is right. The execution, for the most part, is not.
Think about what we are asking women to do. Strap on a device. Track your cycle, your hormones, your perimenopause transition. Receive notifications all week. Cross-reference your app with your wearable with your clinic portal. Then interpret the results yourself.
And if you cannot interpret them, if you are just a person trying to understand your own body, what exactly have we given you? A paid subscription to more cortisol.
Data without a decision pathway does not reduce health anxiety. It manufactures it. It creates the illusion of control while removing the substance of it. You are not managing your health. You are monitoring it obsessively, continuously, and without clinical guidance.
That is not technology serving people. That is surveillance with a subscription fee.
The wellness device loophole : 'Commercialisation of a Medical device' and the 'Medicalisation of a Commercial device'
There is a phrase worth understanding here. The difference between the commercialisation of a medical device and the medicalisation of a commercial device.
Most consumer biosensor products in the FemTech space are built on the second model. They are carefully designed to look and feel like health tools while technically remaining consumer wellness products. Why? Because the moment a device makes a clinical claim it becomes a medical device. And medical devices require regulatory approval, clinical trials, performance validation, and post-market surveillance.
That is expensive. That is slow. And it carries liability.
So instead, most companies measure everything and recommend nothing. They measure but do not diagnose. They trend but do not recommend or guide. This is not a coincidence. It is a deliberate design choice driven by the desire to reach market quickly without regulatory submission, clinical trials, or the accountability that comes with making clinically actionable claims.
The result is a product category that is commercially successful and clinically hollow. A biosensor that cannot tell you what to do with its output is not a health tool. It is a data collector dressed as one.
What meaningful actually can look like : Validation, Decision Architecture, Clinical AI
A biosensor platform that genuinely serves the patient needs three things.
The first is clinical validation, not just analytical validation. Measuring a hormone accurately in a lab is one standard. Demonstrating that the measurement leads to meaningful outcomes in real women, across diverse populations, across the full perimenopause transition, is a completely different standard. Most consumer FemTech devices have the first. Very few have the second.
The second is a decision architecture, not just a data display. The output of a biosensor should not be a number. It should be a recommendation. Not “your LH is elevated” but “based on your LH trajectory, your FSH baseline, and your cycle history, your fertility window opens in approximately 36 hours and here is what that means for you specifically.” The difference between those two sentences is the difference between noise and signal.
The third is AI that actually earns the word clinical. The AI layer in most FemTech platforms today is pattern recognition dressed as intelligence. It finds trends, clusters users, and predicts what the average woman in your cohort does next. But hormonal health is not average and perimenopause does not follow a template.
A woman whose FSH has been climbing for eight months, whose sleep has shifted, whose cycle length has become unpredictable, does not need a trend line. She needs a personalised model that integrates her longitudinal data, flags clinically significant changes, and surfaces recommendations specific to her biology. Recommendations that are evidence-based, auditable, and defensible under regulatory scrutiny. That is clinical AI. Not the word used as marketing. The actual thing.
The perimenopause gap : The Neglect
Perimenopause deserves its own conversation because it represents the most significant neglected opportunity in women’s health diagnostics today.
This is a transition that affects every woman who lives long enough to experience it. It spans four to ten years and is characterised by profound hormonal variability including changes in cycle length, cardiovascular risk, bone density, and cognitive function. And it is almost entirely invisible to current healthcare infrastructure until it is significantly advanced.
Most women in perimenopause do not receive a diagnosis. They receive a dismissal. Their symptoms are attributed to stress, to aging, to anxiety. The hormonal changes underneath are not measured because the tools to measure them continuously, outside a clinic, in the real world, have not existed at the required standard.
A biosensor platform that could track LH, FSH, and estradiol,etc. through the perimenopause transition, model the hormonal trajectory of an individual woman, identify the inflection points that carry clinical significance, and connect that data to a real clinical pathway, would not be a wearable. It would be a public health intervention.
A Different standard : Decision not Noise
The female body has been under-studied, under-diagnosed, and under-served by healthcare for too long. Biosensor technology now exists that could genuinely change that, but only if we build it to a standard that matches the problem.
The devices that will matter, for women navigating fertility challenges, perimenopause transitions, and hormonal complexity, will be built with clinical validation as non-negotiable, regulatory rigour as a foundation, and AI that serves the patient rather than the dashboard.
Everything else is noise. And we have been surrounded by noise for long enough.
Highlights
#FemTech #WomensHealth #Biosensors #Perimenopause #HormonalHealth #DigitalHealth #MedTech #ClinicalAI #PointOfCare #HealthInnovation
